ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pediarix

Also written as “Pediarix”, “Infanrix™ penta” and “Infanrix penta”.

Its studies are mostly in Haemophilus Infections · Rotavirus Infections · Hepatitis B, led by 2 companies.

Drug pagePediarix: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 9, 20069 company-led studies, 1 open or runningNext primary completion: Nov 6, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only80 open or runningphase 3since Feb 9, 2006Aug 10, 2005none ahead
Pfizer11 open or runningphase 3since Aug 14, 2025Aug 14, 2025Nov 6, 2028phase 3 · NCT07160244

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2025First study: phase 3 study in HealthyFirst studyNCT07160244 · 6,000 planned · United States, Argentina, Brazil and more

Ahead

  1. Nov 6, 2028Primary completion: phase 3 study in HealthyNCT07160244

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of detoxified tetanus toxoid, detoxified diphtheria toxoid, acellular pertussis antigens, inactivated poliovirus (IPV) types 1,2 and 3 and hepatitis B (HBV) surface antigen, with active immunizing activities against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis”NCIt, by rule

Studies

The one study Pfizer leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160244Healthy · United States, Argentina, Brazil and more3RecruitingNov 6, 20286,000

How it is read

Names in the registry

  • “Pediarix”, 3 entries
  • “Infanrix™ penta”, 2 entries
  • “Infanrix penta”, 1 entry
  • “Infanrix penta ®”, 1 entry
  • “Pediarix™”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.